Atlas Trials

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Clinical trial NCT05935579 · UNKNOWN

Trial details

NCT number
NCT05935579
Sponsor
Peking Union Medical College Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract NeoplasmsImmunotherapy
Start date
2022-12-14
Primary completion
2023-12-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.